Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05965388Not Yet Recruiting

Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Role: lead

NCT04946682Not ApplicableUnknown

Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment

Role: lead

NCT03448744Phase 4Unknown

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Role: lead

All 3 trials loaded